The results of the trial were published in the journal Nature Medicine.
The trial was conducted by researchers at the University of California, San Diego School of Medicine and the University of California, San Francisco. The researchers tested a new drug called T-DM1 on patients with advanced melanoma.
T-DM1 is a form of immunotherapy that uses a patient’s own immune system to fight cancer. It is made up of two drugs: a monoclonal antibody that targets the cancer cells and a toxin that is attached to the antibody. The toxin is released when the antibody attaches to the cancer cells. The researchers found that T-DM1 was able to shrink tumors in 12 out of 16 patients. The drug also increased the amount of time before the cancer returned in some patients.
Deep Patient was able to predict the effectiveness of the drug in patients and how well the drug would work in patients with melanoma. The researchers used a machine learning algorithm called Deep Patient, which is based on Google’s DeepMind.
Deep Patient uses medical records and other data from previous trials of cancer drugs to make predictions about new drugs.